Trevi Therapeutics, Inc. ( TRVI) Stock. Should you Buy or Sell? $ 3.25
0.06 (1.81 %)
Trevi Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | TRVI |
| Price | $3.25 |
| Beta | 0.209 |
| Volume Avg. | $1.54 M |
| Market Cap | $139 M |
| 52 Week Range | $0.46 - $4.683 |
Trevi Therapeutics, Inc. opened the day at $3.25 which is +'1.81 % on yesterday's close. Trevi Therapeutics, Inc. has a 52 week high of $4.683 and 52 week low of $0.46, which is a difference of $4.223. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $139 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Trevi Therapeutics, Inc. for $139 M, it would take 15 years to get your money back. Trevi Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Trevi Therapeutics, Inc. Stock Forecast - Is Trevi Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -6.211 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Trevi Therapeutics, Inc.
| Price Book Value Ratio | 3.198 | Price To Book Ratio | 3.198 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -6.211 |
How liquid is Trevi Therapeutics, Inc.
| Current Ratio | 5.176 |
| Quick Ratio | 5.045 |
Debt
| Debt Ratio | 0.257 | Debt Equity Ratio | 0.345 |
| Long Term Debt To Capitalization | 0.082 | Total Debt To Capitalization | 0.171 |
Latest news about Trevi Therapeutics, Inc.
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit (In-person) Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants.
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
About Trevi Therapeutics, Inc.
Description :
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
